Apatinib in combination with S-1 as first-line treatment in patients with advanced gastric cancer: A phase II clinical trial.

被引：0
|
作者：
Zhang, Chuantao
Liu, Zimin
Zhou, Na
Zhang, Jianli
Zhu, Jingjuan
Lv, Hongying
Li, Tianjun
Hou, Helei
Liu, Dong
Cong, Jing
Jiang, Man
Liu, Kewei
Cui, Zhumei
Zhou, Yanbing
Zhang, Xiaochun
机构：
[1] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[2] Qingdao Univ Hosp, Qingdao, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.71
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer
    Toh, U.
    Yamana, H.
    Koufuji, K.
    Mine, T.
    Aoyagi, K.
    Miyagi, M.
    Imaizumi, T.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
    Zhou, Na
    Zhang, Chuantao
    Liu, Dong
    Liu, Kewei
    Wang, Guanqun
    Zhu, Hua
    Zhang, Jianli
    Jiang, Man
    Liu, Ning
    Zhang, Xiaochun
    ONCOLOGIST, 2021, 26 (03): : E374 - E381
  • [3] A PHASE II CLINICAL TRIAL OF PACLITAXEL/CISPLATIN/S-1 TRIPLET COMBINATION CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER AS FIRST-LINE THERAPY
    Song, H. S.
    Do, Y. R.
    Lee, W. S.
    Kim, J. G.
    Chae, Y. S.
    Lee, K. H.
    Kim, M. K.
    Rhoo, H.
    Park, K.
    Baek, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 173 - 173
  • [4] A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    Yang Lin
    Song Yan
    Zhou Ai-ping
    Qin Qiong
    Chi Yihebali
    Huang Jing
    Wang Jin-wan
    CHINESE MEDICAL JOURNAL, 2013, 126 (18) : 3470 - 3474
  • [5] Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
    Hou, Zhenyu
    Zhu, Keyun
    Yang, Xuejiao
    Chen, Ping
    Zhang, Wei
    Cui, Yunlong
    Zhu, Xiaolin
    Song, Tianqiang
    Li, Qiang
    Li, Huikai
    Zhang, Ti
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [6] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
    Chikara Kunisaki
    Masazumi Takahashi
    Hirochika Makino
    Takashi Oshima
    Shoichi Fujii
    Ryo Takagawa
    Jun Kimura
    Takashi Kosaka
    Hidetaka A. Ono
    Hirotoshi Akiyama
    Kunio Kameda
    Fumihiko Kito
    Satoshi Morita
    Itaru Endo
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1363 - 1368
  • [7] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
    Kunisaki, Chikara
    Takahashi, Masazumi
    Makino, Hirochika
    Oshima, Takashi
    Fujii, Shoichi
    Takagawa, Ryo
    Kimura, Jun
    Kosaka, Takashi
    Ono, Hidetaka A.
    Akiyama, Hirotoshi
    Kameda, Kunio
    Kito, Fumihiko
    Morita, Satoshi
    Endo, Itaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1363 - 1368
  • [8] A phase II study of S-1 and irinotecan combination chemotherapy in patients with advanced gastric cancer as a first-line therapy
    Ryoo, B. Y.
    Kang, H. J.
    Yang, S. H.
    Cho, S. H.
    Oh, S. J.
    Lee, M. H.
    Song, E. K.
    Chung, H. C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 274 - 274
  • [9] A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    YANG Lin
    SONG Yan
    ZHOU Ai-ping
    QIN Qiong
    CHI Yihebali
    HUANG Jing
    WANG Jin-wan
    中华医学杂志（英文版）, 2013, 126 (18) : 3470 - 3474
  • [10] A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer
    Sung Yong Oh
    Hyuk-Chan Kwon
    Sang-Ho Jeong
    Young-Tae Joo
    Young-Joon Lee
    Su hee Cho
    Myoung Hee Kang
    Se-il Go
    Gyeong-won Lee
    Hoon gu Kim
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 350 - 356
12345